CD20

CD20 is a protein that is encoded by the MS4A1 gene in humans. It is a B-lymphocyte surface molecule involved in the development and differentiation of B-cells into plasma cells. CD20 is widely used as a target for the treatment of B-cell lymphomas and leukemias.

Structure

CD20 is a non-glycosylated phosphoprotein with a molecular weight of approximately 33-37 kDa. It spans the cell membrane four times, creating two extracellular loops, one intracellular loop, and both the N- and C-termini are located within the cytoplasm.

Function

CD20 plays a crucial role in the regulation of B-cell activation and proliferation. It is involved in the transmembrane calcium channel activity, which is essential for B-cell receptor (BCR) signaling. The exact mechanism of CD20 function is not fully understood, but it is known to be important for the optimal immune response.

Clinical Significance

CD20 is an important target in the treatment of B-cell malignancies. Monoclonal antibodies such as rituximab, ofatumumab, and obinutuzumab target CD20 and are used in the treatment of diseases like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. These therapies work by binding to CD20 on the surface of B-cells, leading to cell death through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis.

Research

Ongoing research is focused on understanding the precise role of CD20 in B-cell physiology and its potential as a therapeutic target. Studies are also exploring the development of new CD20-targeting agents and combination therapies to improve treatment outcomes for patients with B-cell malignancies.

Related Pages

• B-cell
• Lymphoma
• Leukemia
• Monoclonal antibody
• Rituximab
• Ofatumumab
• Obinutuzumab